PDAC fibrosis compromises drug delivery, impedes immune cell accessibility and promotes disease aggression and therapy resistance 1-4 . Inhibition of stromal sonic hedgehog (SHH) signaling in a mouse model has been shown to significantly reduce fibrosis and increase drug update to stabilize, at least transiently, the disease 5 . Similarly, using hyaluronidase to reduce the abundance of mouse tumor hyaluronan and treating xenografted human pancreatic tumors with an angiotensin inhibitor to reduce tissue tension facilitate chemotherapy delivery 1, 6 . But phase 2 clinical trials targeting fibrosis did not increase patient survival 7 . Experiments in mouse models of PDAC revealed that, although depletion of proliferating α-smooth muscle actin (α-SMA)-positive stromal cells reduced fibrosis, the vasculature remained abnormal and the tumors were hypoxic and less differentiated, resulting in accelerated mortality 8 . Additionally, despite a reduction in fibrosis and enhancement of tissue vascularity, genetic ablation of SHH or treatment with a smoothened inhibitor resulted in mouse PDACs that were less differentiated and more aggressive 9 .
At first glance, these data imply that the stroma can both promote and restrain tumor progression and suggest stromal dependency may be context dependent. Nevertheless, these experimental and clinical manipulations were based on presumed similarities in tissue across PDACs regardless of tumor genotype; mediation of stromal remodeling in PDACs by a uniform population of stromal fibroblasts; and comparable physical impacts of fibrosis, including the restraint of tumor cells, impedance of tumor-associated vasculature and prevention of immune infiltratation [10] [11] [12] . Yet the extent, nature and tumor cell response to tumor-associated fibrosis varies widely across cancers, tumor subtypes and even within the same tumor; the stromal cells that contribute to extracellular matrix (ECM) deposition and remodeling in tumors are heterogeneous [13] [14] [15] [16] . Importantly, oncogenic transformation itself increases tumor cell tension, which can critically contribute to ECM remodeling and the malignant phenotype, as was demonstrated by a Ras-transformed epithelium whose ROCK-dependent contractility and fibrosis induction was essential for Wnt-dependent squamous Fibrosis compromises pancreatic ductal carcinoma (PDAC) treatment and contributes to patient mortality, yet antistromal therapies are controversial. We found that human PDACs with impaired epithelial transforming growth factor-b (TGF-b) signaling have high epithelial STAT3 activity and develop stiff, matricellular-enriched fibrosis associated with high epithelial tension and shorter patient survival. In several KRAS-driven mouse models, both the loss of TGF-b signaling and elevated b1-integrin mechanosignaling engaged a positive feedback loop whereby STAT3 signaling promotes tumor progression by increasing matricellular fibrosis and tissue tension. In contrast, epithelial STAT3 ablation attenuated tumor progression by reducing the stromal stiffening and epithelial contractility induced by loss of TGF-b signaling. In PDAC patient biopsies, higher matricellular protein and activated STAT3 were associated with SMAD4 mutation and shorter survival. The findings implicate epithelial tension and matricellular fibrosis in the aggressiveness of SMAD4 mutant pancreatic tumors and highlight STAT3 and mechanics as key drivers of this phenotype. a r t i c l e s 4 9 8 VOLUME 22 | NUMBER 5 | MAY 2016 nature medicine carcinoma progression [17] [18] [19] . Sorting out the contribution of stromal and epithelial elements to PDAC fibrosis and pathology would go far in guiding the development and application of antistromal therapies. Patients whose tumors harbor mutations in mothers against DPP homolog 4 (SMAD4) die more frequently from disseminated disease 20 , and reduced levels of epithelial SMAD4 were shown to enhance the aggressiveness and dissemination of tumor cells from PDACs in an experimental mouse model 21 . Interestingly, experimental tumors with combined Kras mutations and Tgfbr2 deletion are highly fibrotic and exhibit a pronounced mesenchymal-like phenotype following stromal ablation 8, 22 . Clinically, patient PDACs with a quasi-mesenchymal phenotype are more aggressive and resistant to treatment than PDACs with a classical, more differentiated histophenotype 23, 24 . Moreover, mesenchymal-like patient PDACs are often associated with aberrant TGF-β signaling in the epithelium 25 . These findings suggest that PDACs in which TGF-β signaling is compromised may have a unique stromalepithelial interaction phenotype that could influence their response to antistromal therapies. As such, we investigated the interplay between tumor genotype and fibrotic phenotype in PDAC progression.
RESULTS

Tissue tension and collagen thickness link to PDAC prognosis
Fibrillar collagen has been implicated in PDAC aggression and treatment resistance 26 , yet recent findings suggest collagen abundance in PDAC may be associated with better, not worse, patient prognosis and with a more differentiated PDAC phenotype [27] [28] [29] . We constructed a gene list of major fibrillar collagens ( Supplementary Table 1 ) and used this signature to stratify publicly available PDAC data (GEO GSE21501). We found no significant association between expression of the major fibrillar collagens and patient survival. However, when we stratified patient data according to expression of collagens Col1α2, Col2α1 and Col4α1, we found that patients expressing high levels of these specific collagens had lower overall survival (log-rank P ≤ 0.04) ( Supplementary Fig. 1a) .
To investigate the relationship between fibrillar collagen and PDAC phenotype, we assessed total and fibrillar collagen in PDAC tissue arrays with well-differentiated (n = 19), moderately differentiated (n = 23) and poorly differentiated (n = 26) tumors. Although total and fibrillar collagens were similar in all tumor biopsies regardless of differentiation status ( Fig. 1a and Supplementary Fig. 1b,c) , we noted a reduction in number of α-SMA-positive cells in the poorly differentiated PDAC tumor biopsies, compared to the well-differentiated and moderately differentiated tumors 8, 30 (Fig. 1a ) (P ≤ 0.05). Moreover, the diameter of the collagen fibers adjacent to the epithelial lesions was significantly greater in the poorly differentiated PDACs (Fig. 1) (P ≤ 0.01-0.001). We also detected a progressive increase in level of phosphorylated myosin light chain-2 (p-MLC2) in the epithelium adjacent to the thicker collagen fibers in the moderately and poorly differentiated tumors, which is consistent with increased epithelial actomyosin tension ( Fig. 1a ) (P ≤ 0.05-0.001) and suggests that an association may exist between tumor cell tension and the architecture of the adjacent collagen bundles 19, 31 .
To investigate the relationship between fibrillar collagen, epithelial tension and patient survival, we stratified PDAC tumors from a cohort of patients 32 by survival (median survival <10 months versus median survival >24 months). Again, we found no association between total and fibrillar collagen or α-SMA-positive cells and patient survival ( Fig. 1b and Supplementary Fig. 1d,e ). However, the diameter of the collagen fibers adjacent to the pancreatic lesions was significantly thicker in patients with the shortest survival ( Fig. 1b ) (P ≤ 0.001). We also observed elevated p-MLC2 in the PDAC tissues from patients with the shortest survival, indicating increased actomyosin tension and a relationship between the contractile PDAC epithelium and the reorganized collagen bundles ( Fig. 1b) (P ≤ 0.001). TGF-β signaling is often attenuated in patient PDACs 33 , thus we assessed phosphorylation of SMAD2 (p-SMAD2) as a primary mediator of canonical TGF-β signaling. We detected less p-SMAD2 in the least-differentiated PDAC lesions ( Fig. 1a ) (P ≤ 0.001) and the PDACs derived from the patients with the shortest survival ( Fig. 1b ) (P ≤ 0.001), suggesting they had compromised TGF-β signaling 34, 35 . Next, we compared the stromal phenotype of patient PDACs with genetically altered SMAD4 to PDACs with wild-type SMAD4 (ref. 36) . Although total collagen and α-SMA levels were similar between the cohorts (Supplementary Fig. 1f ), we observed elevated epithelial p-MLC2 ( Fig. 1c ) (P ≤ 0.001) with increased adjacent collagen fibers in PDACs lacking functional SMAD4 ( Fig. 1c) . Atomic force microscopy (AFM) mechanical testing revealed that the thickened, epithelial-adjacent collagen fibers were stiffer in the PDACs from patients whose lesions lacked a functional SMAD4 ( Fig. 1c ) (P ≤ 0.001). These findings indicate that the architecture and mechanics of collagen fibers adjacent to the epithelial lesion, and not bulk collagen abundance, may be an indicator of PDAC aggression and that a reduction in TGF-β signaling in the PDAC epithelium may influence the nature of the stromal response.
PDAC genotype tunes epithelial tension to regulate fibrosis
To explore the relationship between TGF-β signaling, collagen organization and tissue mechanics, we exploited three genetically engineered PDAC mouse models: KC (Kras LSL-G12D/+ Ptf1α-Cre) 37 , KPC (Kras LSL-G12D/+ Tp53 R172H/+ Pdx1-Cre) and KTC (Kras LSL-G12D/+ Tgfbr2 flox/+ Ptf1a-Cre, which bears a loxP-flanked allele of Tgfbr2) mice. By age 20 weeks, KC mice had progressed to pancreatic intraepithelial neoplasia (PanIN) lesions, whereas KPC and KTC mice developed PDAC lesions 22, 38 . Coincident with tumor formation, the pancreatic tissues of both KPC and KTC mice were highly fibrotic, as indicated by abundant total and fibrillar collagen (data not shown). Targeted proteomics confirmed that many fibrillar collagens in KTC and KPC mice were present at similar levels ( Supplementary Table 2 ). Immunofluorescence staining showed that KTC and KPC tumors had similar stromal levels of collagen III, α-SMA and fibroblastactivated protein (FAP) (Supplementary Fig. 2a ). GLI family zinc finger 1 (GLI1), which regulates PDAC fibrosis, was abundantly a r t i c l e s 5 0 0 VOLUME 22 | NUMBER 5 | MAY 2016 nature medicine and uniformly expressed in the KPC and KTC tumor stroma ( Supplementary Fig. 2a ). Nevertheless, and in agreement with our clinical findings, KTC PDAC lesions had thicker collagen bundles and a stiffer ECM in the periductal region ( Fig. 2a -c) (P ≤ 0.001). Mass spectrometry and immunofluorescence analyses of the tumor ECM further revealed that the altered fibrillar collagen phenotype and the elevated ECM stiffness in KTC PDAC lesions was accompanied by a significant increase in tenascin C, fibronectin and collagen type XII α1 (P ≤ 0.05) ( Supplementary  Fig. 3b , Supplementary Table 2 and Fig. 2a,b) . The KTC PDAC epithelium was also more contractile, as indicated by more p-MLC2 and myosin phosphatase target subunit 1 (p-MyPT1) ( Fig. 2a and Supplementary Fig. 3a ) (P ≤ 0.01-0,001) and higher mechanosignaling, as indicated by activated β1-integrin, phosphorylated focal adhesion kinase ( p397 PTK2) ( Fig. 2a and Supplementary Fig. 3a ) (P ≤ 0.05-0.01) and nuclear Yorkie activated protein (YAP1) 39 ( Fig. 2a and Supplementary Fig. 3a ) (P ≤ 0.01-0.001). These data suggest that a reduction in TGF-β signaling increases actomyosin tension and mechanosignaling in a transformed pancreatic epithelium to induce a stiffer, periductal, matricellular-enriched fibrosis.
We next assessed the contractility phenotype of individual PDAC epithelial cells derived from KC, KTC and KPC mice using traction force microscopy (TFM). KTC tumor cells were more contractile than the KPC or KC cells ( Supplementary Fig. 3c ). KTC tumor cells promoted more Rho kinase-1 (ROCK1)-dependent but not ROCK2-dependent 3D collagen gel contraction than KPC or KC tumor cells ( Supplementary Fig. 4a ) (P ≤ 0.01-0.001) ( Fig. 2d and Supplementary Fig. 5a-d) . The KTC tumor cells exhibited higher ROCK1-dependent tumor growth ( Supplementary Fig. 4d ). Myosin tension, as indicated by elevated traction force as well as p-MLC2 ( Fig. 2e and Supplementary Fig. 4c ), induced more nuclear YAP1 and YAP activity, as indicated by higher Ctgf expression ( Supplementary  Fig. 4f ), and promoted greater fiber diameter ( Fig. 2f) . Fibers were also stiffer and enriched for the matricellular protein tenascin C ( Fig. 2g-i ) upon orthotopic injection of KTC cells into the pancreas of immunocompromised mice. These data demonstrate that a reduction of TGF-β signaling in the pancreatic epithelium increases tumor cell tension to induce a stiffer, matricellular fibrosis.
KTC tumor cells also showed a significant increase in anchorageindependent growth and colony formation ( Supplementary Fig. 4f ) (P ≤ 0.05-0.001), which is consistent with a reduced dependence npg on ECM ligation for tumor cell survival and the enhanced metastasis incidence observed in patients with mutant SMAD4 (refs. 20,40) . However, the size of the KTC tumors was significantly smaller (P < 0.0001) than those formed by KPC cells ( Supplementary  Fig. 4d,e ). Thus, although pancreatic transformation is universally accompanied by progressive fibrosis and stiffening of the ECM, the nature of the fibrotic response and the mechanophenotype of the cancer can be modified by the genotype of the tumor.
JAK-STAT3 signaling drives ECM remodeling and stiffening
We next sought to clarify how reduced TGF-β signaling could increase tumor cell tension. G-protein-coupled-receptor-mediated Janus kinase (JAK) activation stimulates activation of both signal transducer and activator of transcription-3 (STAT3) and ROCK1 and induces actomyosin-mediated cell contractility, and STAT3 has been implicated in PDACs [41] [42] [43] [44] [45] . We observed significantly more p-STAT3 (P ≤ 0.001) in the pancreatic epithelium of KTC mice than in KPC or KC mice (Fig. 3a) , even in PanINs from 8-week-old mice, where the amount of infiltrating immune cells was very low (Supplementary Fig. 6a) . Although both the stroma and the PDACs in KPC and KTC mice stained positively for p-STAT3 (coincident with an abundant immune infiltrate) 45 , p-STAT3 was significantly higher (P ≤ 0.001) only in the tumor pancreatic epithelium in KTC mice (Fig. 3a) . We also detected abundant p-STAT3 in vitro in nonstimulated KTC, but not KPC or KC, cells ( Fig. 3b and Supplementary Fig. 5a ). KTC tumor cell contraction and remodeling of collagen gels was blocked by treatment with the JAK inhibitor ruxolitinib (Fig. 3c,d and Supplementary Fig. 6b ). We cultured KTC cells for 48 h, collected the medium (conditioned medium) and used it to treat KC cells. We noted that the conditioned medium activated p-STAT3 in cultured KC cells ( Fig. 3e ) and simultaneously increased the JAK-dependent ability of the KC cells to contract and remodel collagen gels ( Fig. 3f and Supplementary Fig. 6c) .
A stiff ECM can enhance STAT3 activation 46 , and we observed higher steady-state p-STAT3 levels in KC tumor cells and higher levels of secreted cytokines in KTC-conditioned medium when they were plated on a stiff ECM (Fig. 3f-i and Supplementary Fig.  6d-f) . These findings identify an epithelial JAK-ROCK-STAT3 signaling circuit as a candidate KTC tumor-cell-specific contractility mechanism that could induce ECM remodeling and foster the development of matricellular-enriched pancreatic fibrosis.
Tumor cell tension accelerates PDAC progression in mice
To test links between p-STAT3, tumor tension and fibrosis in PDAC progression, we crossed transgenic mice expressing Ptf1α-Cre with mice expressing a conditional V737N mutation in β1-integrin (β1-V737N mice) ( Supplementary Fig. 7a) , which recapitulates tensiondependent integrin clustering and promotes focal adhesion signaling and ROCK-dependent cell contractility in the pancreatic epithelium 18, 47, 48 .
Immunofluorescence staining in the resulting β1-V737N mice confirmed elevated PTK2 activity (P ≤ 0.001) in the pancreatic epithelium and revealed higher epithelial contractility, as indicated (Supplementary Fig. 7b) , and second-harmonic generation revealed thicker, denser collagen (data not shown). AFM mechanical testing showed a significant (P ≤ 0.001) stiffening of the ECM surrounding the ductal epithelium ( Supplementary Fig. 7b) .
The presence of p-STAT3-positive pancreatic epithelial cells in β1-V737N mice (P ≤ 0.05), even in the absence of activating oncogene or pre-existing inflammation, confirmed that epithelial tension can directly enhance STAT3 activation, altered cytokine expression and immune cell infiltration ( Supplementary  Fig. 7b-e ). Consistently with these results, treatment of the β1-V737N mice with a PTK2 inhibitor reduced p-STAT3, p397 PTK2 and p-MLC2 abundance as well as matricellularenriched fibrosis (Supplementary Fig. 8a) . Orthotopic injection of KTC cells expressing a short hairpin RNA (shRNA) against PTK2 ( Supplementary Fig. 9a,b ) into immunocompromised mice also reduced fibrosis (P ≤ 0.001), decreased stiffness (P ≤ 0.01) and lowered tenascin C levels (P ≤ 0.001) toward those of control tumors. The pancreatic tumor epithelium expressing shRNA against Ptk2 was less mechanically activated than tissue expressing scramble shRNA (controls), as indicated by reduced nuclear YAP1 (P ≤ 0.001), and had lower levels of nuclear p-STAT3 (P ≤ 0.001) ( Fig. 4) than control tumors. To assess the relationship between epithelial tension and PDAC development, we bred Ptf1a-Cre/β1-737N mice with KC mice by increased p-MLC2 (P ≤ 0.001), and higher mechanosignaling, as indicated by nuclear localization of YAP targets including Ctgf (P ≤ 0.05; Supplementary  Fig. 7b,c) . Evidence of fibrosis was indicated by increased picrosirius red stain-( Fig. 4a) and found that the pancreatic epithelium in 5-week-old KC mice expressing β1-V737N (KC/β1-V737N mice) had significantly higher p397 PTK2 (P ≤ 0.001) and p-MLC2 (P ≤ 0.01) than KC mice. The amount and distribution of collagen fibers and ECM stiffness were highest in the periductal region (Fig. 4b) , similarly to our observations in the developing KTC lesions ( Figs. 2a and 4b) .
Consistent with the matricellular-enriched fibrosis observed in both the patient samples lacking p-SMAD and the PDAC lesions in the KTC mice, we detected abundant tenascin C and higher levels of epithelial p-STAT3 in the KC/β1-V737N tumors (Fig. 4b) . This phenotype was accompanied by an increase in infiltrating CD68 + macrophages (Fig. 4b) , and FACS characterization of the immune cell population revealed an increase in CD45 + CD11b myeloid cells and CD45 + Ly6C monocytes (Supplementary Fig. 9d) . Indeed, cytokine array analysis showed higher levels of proinflammatory factors C5α and IL1 in the pancreas in KC/β1-V737N mice than in KC mice ( Supplementary  Fig. 9e) . Chronic pancreatitis was detectable in KC/β1-V737N mice by 3 months of age (Fig. 4c) . Alcian blue staining of pancreatic tissue from 3-month-old KC/V737N mice showed that the lesions had progressed to advanced, high-grade PanINs and that these foci were evenly distributed throughout the tissue. By age 5-8 months, 38% of KC/β1-V737N mice developed frank PDACs with accompanying physiological trauma, including loss of body weight ( Fig. 4d and  Supplementary Fig. 9c ). Orthotopic KTC tumor showed a marked loss of stromal fibrosis and matrix remodeling upon knockdown of Ptk2 compared to scrambled controls (Fig. 4e,f) . These results reveal that increasing the cytoskeletal contractility in pancreatic tumor cells drives remodeling and stiffening of the periductal ECM, induces matricellular-enriched fibrosis and promotes pancreatic transformation.
STAT3 induces fibrosis and accelerates PDAC
We next explored the relationship between STAT3 activation, cell contractility and pancreatic matricellular-enriched fibrosis in PDAC. We crossed KC mice to mice expressing one allele of a constitutively active Stat3 (ref. 49) (Fig. 5a) . The resulting STAT3C mice contained significantly more p-STAT3-positive cells in the pancreas (Supplementary Fig. 10a ) (P ≤ 0.001), and the level of p-STAT3 was further increased after expression of activated KRAS (Fig. 5b) compared to wild-type or Ptf1a-Cre and KC mice, respectively. We observed higher numbers of CD45 + immune cells (P ≤ 0.001) and CD68 + macrophages (P ≤ 0.05) within the STAT3C pancreatic tissues (Supplementary Fig. 10a) ; these immune infiltrates further increased with KRAS activation (Fig. 5b) . Indeed, the pancreatic tissues in constitutively active STAT3 mice crossed to the KC model (KC/Stat3C mice) showed marked pancreatitis that developed into frank PDAC and shortened survival compared to KC mice (Fig. 5c) . Consistent with a link between STAT3 and ROCK, although tumors were stiffer and p-MLC2 was abundant in the KC/STAT3C mice, p-MLC2 levels were elevated significantly (P ≤ 0.001) in the pancreatic tissue of STAT3C mice even in the absence of KRAS (Fig. 5b,d and Supplementary Fig. 10a ). The pancreas of STAT3C mice contained abundant mature type I collagen (Supplementary Fig. 10a ) (P ≤ 0.005) and elevated p397 PTK2 throughout ( Supplementary  Fig. 10a ) (P ≤ 0.05). These findings link STAT3 activation and tissue inflammation and suggest that p-STAT3 induces ROCKdependent ECM remodeling and stiffening to drive fibrosis and elevate mechanosignaling in PDACs.
To establish a causal relationship between STAT3 activation, tissue mechanics and matricellular-enriched fibrosis and PDAC development, we crossed mice expressing KRAS and homozygous for loss of Tgfbr2 (ref. 21) (Kras LSL-G12D/+ Tgfbr2 flox/flox (KTC-KO) mice), which exhibit an accelerated matricellular-enriched fibrotic phenotype and PDAC development (Supplementary Fig. 10a-c) , with STAT3-KO mice, which carry a conditional Stat3 knockout 50 in the pancreatic epithelium (Stat3 flox/flox ;Ptf1α-Cre) to generate KTC-KO/STAT3-KO mice (Fig. 5e) . Immunostaining confirmed deletion of STAT3 in the pancreatic epithelium (Fig. 5f) accompanied by significantly reduced CD68 + cell tissue infiltration (P ≤ 0.001), consistent with decreased inflammation (Fig. 5f) . Loss of epithelial STAT3 was also accompanied by a significant reduction in epithelial p397 PTK2, p-MLC2 and nuclear YAP1 (P ≤ 0.001) as well as YAP transcriptional activity, as indicated by significantly lower Ctgf expression ( Fig. 5f and Supplementary Fig. 9b ) (P ≤ 0.05). Pancreatic tissues lacking epithelial STAT3 showed significant reduction in matricellular-rich fibrosis and ECM stiffness (P ≤ 0.001) and a significant increase in mouse survival (Fig. 5f-h) .
Direct links between a matricellular-rich fibrotic phenotype, mechanics and p-STAT3 were confirmed in a cohort of KTC mice treated with the JAK inhibitor ruxolitinib. Ruxolitinib treatment inhibited p-STAT3 activity and significantly reduced p397 PTK2, p-MLC2, collagen fibrillogenesis, matricellular matrix enrichment and ECM stiffening ( Supplementary Fig. 11c,d) (P ≤ 0.01-0.001) as well as YAP activation (data not shown). Moreover, in the absence of JAK-driven matricellular-rich fibrosis, mechanosignaling, STAT3dependent inflammation and PDAC development were significantly reduced (Supplementary Fig. 11c,e ) (P ≤ 0.01-0.001).
We investigated the clinical relevance of STAT3 activation in matricellular-enriched fibrosis and PDAC progression, and found elevated levels of tenascin C, fibronectin and collagen 12 (P ≤ 0.05), high nuclear YAP1 (P ≤ 0.05) ( Fig. 6a) and elevated SOX2, vimentin (P ≤ 0.01; Supplementary Fig. 12a ) and p-STAT3 ( Fig. 6a ; P ≤ 0.05) in the mesenchymal-like, vimentin-positive PDAC biopsies excised from patients with shorter median survival. The PDAC tissue with confirmed SMAD4 mutations also had elevated levels of epithelial p-STAT3 (P ≤ 0.001), tenascin C (P ≤ 0.001), fibronectin (P ≤ 0.01) and collagen type XII α1 (P ≤ 0.05) (Fig. 6b) . The epithelium in the PDAC tumors with mutant SMAD4 was more mechanically activated, as evidenced by a significant increase in nuclear YAP1 (P ≤ 0.01). Moreover, the samples with SMAD4 mutations had significantly higher nuclear SOX2 (P ≤ 0.01) and contained significantly more vimentin (P ≤ 0.001), which is consistent with a quasi-mesenchymal phenotype that typically has an aggressive disease pathology (Supplementary Fig. 12b ).
DISCUSSION
Using clinical specimens and experimental mouse models, we identified a unique, highly rigid, matricellular-stromal phenotype linked specifically to a PDAC genotype that results in reduced epithelial TGF-β signaling and elevated tumor cell contractility. Our data suggest that the genetically induced tumor cell tension differentially 'tunes' the composition and mechanics of the periductal stroma in PDACs, regardless of the bulk stromal phenotype, to promote tumor progression and aggression by engaging mechanosignaling pathways linked to integrins and YAP. The findings are consistent with the mathematical predictions identifying two distinct stromal phenotypes termed 'normal' and 'activated' in PDAC subtypes of increasing aggression 24 . Our findings provide the first direct evidence that tumor genotype per se can calibrate tumor cell contractility to modulate the fibrotic phenotype of the tissue and modify the pathology of the cancer. Our data further suggest that bulk collagen content is a poor surrogate for the multifaceted contributions of PDAC fibrosis to cancer aggression and advocate imaging approaches to visualize differential distribution of the stroma such as MR imaging and elastography 51 .
PDAC-associated fibrosis has been viewed as a constraint that directly compromises lymphatic drainage and impedes neovascularization and indirectly increases interstitial fluid pressure to disrupt blood vessel integrity and induce hypoxia 1 . This physical barrier compromises drug delivery, reduces immune cell accessibility and promotes disease aggression and therapy resistance, underscoring the critical importance of tissue mechanics to tumor biology 4, 12, 52 . Notably, our data show that the fibrosis is not merely a passive physical restraint. Rather, the elevated tissue mechanics directly activate key pathways such as integrin-dependent signaling and YAP to promote tumor progression and aggression [10] [11] [12] . To this end, our clinical findings revealed that poorly differentiated PDACs and the PDACs with impaired TGF-β signaling were the most mechanically activated and expressed elevated YAP1 and SOX2, which are transcriptional regulators that have been implicated in tumor aggression and epithelial-to-mesenchymal transition [53] [54] [55] [56] . Indeed, these same YAP1 and SOX2-expressing tumors expressed markers of a mesenchymallike phenotype including vimentin, fibronectin and tenascin C [57] [58] [59] (Fig. 6b) . Our findings thus imply that the more aggressive phenotype of PDACs with a quasi-mesenchymal phenotype may be linked to their altered mechanobehavior. Moreover, given that YAP signaling can drive KRAS-independent PDAC growth and survival, our observations indicate that fibrotic PDAC tumors may naturally evolve toward KRAS independence and that this phenotype will be potentiated by specific tumor genotypes that increase tissue fibrosis including loss of TGF-β signaling. Our data thereby present a plausible reason for the mixed responses of PDAC cancer patients to antistromal therapies, and suggest that PTK2 and JAK inhibitors, which target both stromal-and epithelial-driven fibrosis and reduced YAP1 and tenascin induction in our studies, may comprise more efficacious therapeutic options.
METhODS
Methods and any associated references are available in the online version of the paper. For PTK2 (FAK) inhibition studies, Ptf1a-Cre/β1-V737N mice were treated with FAK inhibitor PND-1186 at 0.5 mg/ml in 5% sucrose in the drinking water, control mice were provided 5% sucrose as drinking water (n = 5 per group). Treatment started at 3 weeks of age. At this time point, mice exhibit pancreatitis and fibrosis at 3 weeks of age and mice were killed after 3 weeks owing to animal protocol guidelines. For JAK inhibition, KTC mice were treated with JAK inhibitor ruxolitinib twice daily by oral gavage at 60 mg per kg body weight (mg/kg) in 0.5% methylcellulose in water. Control mice were provided 0.5% methylcellulose in water (n = 5 per group). Treatment started at 3 weeks and mice were killed after 3 weeks.
For orthotopic xenografts, 5 × 10 5 firefly-luciferase-mApple-expressing cells in Matrigel (BD Biosciences) were injected into the pancreas of 8-week-old nude mice (Simonsen laboratory) (n = 5 per group), and tumor growth was monitored by weekly bioluminescence imaging. Mice were sacrificed at 2 weeks after the cell injection per animal protocol. Female mice were used in the xenograft studies.
For bioluminescence imaging, animals were injected intraperitoneally with 3 mg of d-luciferin and imaged using IVIS spectrum imaging system. Living Image 4.3 was used for analysis of the images after acquisition.
For all animal studies, animals were randomly distributed among different conditions by the investigator as the animals did not show any size or appearance differences at the onset of the experiments. No animals were excluded, and the investigator was not blinded to group allocation during the experiment.
Histology. Paraffin-embedded or fresh-frozen pancreatic tissues were analyzed by hematoxylin and eosin (H&E), picrosirius red, Masson's trichrome or Alcian blue according to the manufacturer's instructions. For mouse and clinical studies, staining intensity of tissue sections was scored by a pathologist blinded to mouse genotype.
LC-MS-MS and LC-SRM proteomic analysis.
Proteomic analysis was performed in triplicate on 5 mg of fresh-frozen KC, KPC, and KTC pancreatic tissues as previously described 60 . Briefly, tissues were milled in liquid nitrogen followed by sequential extraction of cellular proteins, soluble ECM proteins, and insoluble ECM proteins. Tryptic digests of all fractions were analyzed by liquid chromatography-select reaction monitoring (LC-SRM) mass spectrometry (MS). Stable isotope labeled (SIL) peptides were used for absolute quantification of ECM proteins by LC-SRM.
Atomic force microscopy measurements. Atomic force microscopy (AFM) and analysis were performed as previously described 61 . Frozen tissue blocks were cut into 20-µm-thick sections. Prior to AFM measurement, each section was immersed in PBS and thawed at room temperature. The samples were maintained in proteinase inhibitor in PBS (protease inhibitor cocktail, Roche 14 Diagnostics, 11836170001) supplemented with propidium iodide (Sigma P4170, 20 µg/ml) during the AFM session. Five samples for each group were used for AFM quantification of Young's elastic modulus of the cancerassociated stroma. AFM indentations were performed using an MFP3D-BIO inverted optical AFM (Asylum Research) mounted on a Nikon TE2000-U inverted fluorescent microscope as previously described 61 . Briefly, we used silicon nitride cantilevers with spring constant of 0.06 N/m with borosilicate glass spherical tip with 5 µm in diameter (Novascan Tech). The cantilever was calibrated using the thermal oscillation method before each experiment. Samples were indented at a 20 µm/s loading rate, with a maximum force of 2 nN. Five AFM force maps were typically obtained on each sample, each map as a 10 × 10 µm raster series of indentations using the FMAP function of the IGOR PRO build supplied by Asylum Research. The Hertz model was used to determine the elastic properties of the tissue (E1). Tissue samples were assumed to be incompressible and a Poisson's ratio of 0.5 was used in the calculation of the Young's elastic modulus.
Two-photon second-harmonics microscopy and image analysis. Two-photon imaging of pancreatic tissues and collagen gels was performed and quantified as previously described 62 . For two-photon imaging, we used custom resonantscanning instruments based on published designs containing a 5-PMT array (Hamamatsu, C7950) operating at video rate 63 . The setup was used with twochannel simultaneous video rate acquisition via two PMT detectors and an excitation laser (2W MaiTai Ti-Sapphire laser, 710-920 nm excitation range). Second-harmonics imaging was carried out on a Prairie Technology Ultima System attached to an Olympus BX-51 fixed stage microscope equipped with a 25× (numerical aperture (NA) 1.05) water-immersion objective. Unfixed, hydrated samples were exposed to polarized laser light at a wavelength of 830 nm and emitted light was separated with a filter set (short-pass filter, 720 nm; dichroic mirror, 495 nm; band-pass filter, 475/40 nm). Images of x and y planes of 284 by 284 µm at a resolution of 0.656 µm/pixel were captured using Micro-Manager Open Source Microscopy Software (Micro-Manager). Quantification of collagen fibers was achieved by setting a minimal threshold in the secondharmonic signal. The threshold was maintained for all images across all conditions. The area of regions that was covered by the minimal threshold was calculated, and three images per sample were averaged together (ImageJ, Image Processing and Analysis in Java). Collagen fiber diameter data were visualized and analyzed using Imaris (Bitplane AG) and MATLAB (MathWorks).
Cell culture and establishment of primary pancreatic cell lines. Establishment of primary pancreatic tumor cells was performed as described previously 64 . Cells were maintained in RPMI-1640 medium containing 10% FBS (Clontech). All experiments were performed within eight passages to avoid possible gross genomic changes during long-term in vitro culture. Cells were verified by epithelial morphology in two dimensions (2D), expression of the epithelial marker cytokeratin 19 and the ability to form tumors in vivo. Cells were tested for mycoplasma contamination using a commercially available kit (PCR-Mycoplasma Test Kit I/C, Promokine PK-CA91-1024) according to manufacturer's manual at the onset of the study (test was negative) and exhibited no contamination signs after the test. Derivative cells were transduced in vitro with a lentiviral vector encoding firefly Luciferase and mApple fluorescent protein for combined bioluminescent imaging and flow sorting. To ensure that all cell lines expressed similar levels of luciferase, mApple-expressing cells were flow sorted before injection into animals.
Soft-agar assay. Anchorage-independent growth was assessed using a soft-agar assay 65 . In brief, 25,000 cells in 1.5 ml 0.35% agarose containing 1× growth medium were overlaid with 1.5 ml 0.5% agarose containing 1× growth medium, and colonies larger than 30 µm in diameter were scored positive after 14 d.
Lentivirus-mediated shRNA knockdown. Lentiviral shRNA targeting ROCK1, ROCK2 and FAK and nontargeting shRNA control were cloned in the pLKO vector. The clone IDs for shRNA are as follows: sh-ROCK1 (TRCN0000022903), npg
